Bookselling company Orell Füssli Thalia acquired a stake as lead investor in the digital community platform Evrlearn. With the new partnership, both companies are strengthening their educational activities in B2C and B2B.
Tags :Vischer
Alloy Therapeutics, a Boston based biotechnology ecosystem company, has entered into a definitive agreement to acquire deepCDR Biologics, a privately held Basel based developer of deep learning technology for antibody discovery and optimisation. Alloy will
Mainova, an energy supplier based in Frankfurt am Main, has acquired a majority stake in the Bavarian energy service provider mobiheat, including its subsidiaries in Austria and Switzerland, from Energieversorgung Offenbach (EVO) and the mobiheat
Procimmo Swiss Commercial Fund II (PSCFII), an investment fund incorporated under Swiss law, has acquired the Sun and Vsp industry sites from Sun Bürglen and thereby strengthens its real estate portfolio. Vischer advised the
msg systems, an international IT consulting and system integration company based in Munich, has acquired Optravis, a provider of SaaS solutions in operational transfer pricing management based in Basel. The terms of the deal were
Relief Therapeutics, a biopharmaceutical company, has launched a Level 1 American Depositary Receipt (“ADR”) program in the United States. From 18 November 2021, ADRs can be traded over-the-counter. Relief’s ADR program complements the existing main listing of
Vifor Pharma acquires the Swiss firm Inositec, a clinical stage biopharmaceutical company which is developing first-in-class treatments for unmet medical need. Through this acquisitions, Vifor Pharma will be spearheading the vascular calcification field to improve
In a dispute revolving around a fiduciary investment, Vischer successfully represented a Swiss bank. The Vischer team encompassed Thomas Weibel and Raphael Butz (both Litigation and Arbitration, pictured above). Fiduciary investments enable bank customers to
GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round. GlycoEra’s
MiniNaviDent has received an investment by Straumann Holding to further develop and market its Denacam system, a miniaturized dynamic navigation system for dental implants. With the investment, Straumann obtained a 39% stake of mininavident. The two
